Literature DB >> 21343791

Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer.

.   

Abstract

Epithelial ovarian cancer is most commonly detected in an advanced stage, when the overall 5-year survival rate is 20–30%. Detection of early-stage ovarian cancer results in improved survival. Currently, there is no effective strategy for ovarian cancer screening. Women with persistent and progressive symptoms, such as an increase in bloating, pelvic or abdominal pain, or difficulty eating or feeling full quickly, should be evaluated, with ovarian cancer being included in the differential diagnosis. Evaluation of the symptomatic patient includes physical examination and may include transvaginal ultrasonography and measurement of levels of the serum tumor marker CA 125. Patients suspected of having ovarian cancer should be managed by a gynecologic surgeon, such as a gynecologic oncologist, who is trained to perform comprehensive surgical staging and cytoreductive (debulking) surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343791     DOI: 10.1097/AOG.0b013e31821477db

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  17 in total

1.  An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers.

Authors:  Zhen Zhang
Journal:  Rev Obstet Gynecol       Date:  2012

2.  Prophylactic bilateral oophorectomy at time of hysterectomy for women at low risk: acog revises practice guidelines for ovarian cancer screening in low-risk women.

Authors:  C A Larson
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 3.  Cancer Screening and Early Detection in the 21st Century.

Authors:  Jennifer T Loud; Jeanne Murphy
Journal:  Semin Oncol Nurs       Date:  2017-03-23       Impact factor: 2.315

Review 4.  Secondary solid cancer screening following hematopoietic cell transplantation.

Authors:  Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

5.  Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer.

Authors:  J Brian Szender; Shashikant B Lele
Journal:  AMA J Ethics       Date:  2015-09-01

Review 6.  Proteomics of ovarian cancer: functional insights and clinical applications.

Authors:  Mohamed A Elzek; Karin D Rodland
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

7.  Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

Authors:  Gabriel N Mannis; Julia E Fehniger; Jennifer S Creasman; Vanessa L Jacoby; Mary S Beattie
Journal:  JAMA Intern Med       Date:  2013-01-28       Impact factor: 21.873

8.  Endometrial and ovarian cancer in lynch syndrome.

Authors:  Marta Ann Crispens
Journal:  Clin Colon Rectal Surg       Date:  2012-06

9.  Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.

Authors:  Qing H Meng; Enping Xu; Michelle A T Hildebrandt; Dong Liang; Karen Lu; Yuanqing Ye; Elizabeth A Wagar; Xifeng Wu
Journal:  Clin Chem       Date:  2013-10-21       Impact factor: 8.327

Review 10.  In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Authors:  Joshua G Cohen; Matthew White; Ana Cruz; Robin Farias-Eisner
Journal:  World J Biol Chem       Date:  2014-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.